Análisis Argos
FUL
FULCara
H.B. Fuller Company · Basic Materials
US$ 58.06
precio al 2026-07-04
Valor justo Argos*
US$ 31–36
vs. su valor justo
74% por encima
Score Argos
60/100
LA RESPUESTA
El mercado le pide crezca 21.4% al año — más de lo que ha demostrado (3%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Cotiza 28% por debajo de su valor justo.
Las ganancias crecieron 17% el último año.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO4/6
El Iris de calidad
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO4/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos60de 100Cara
Ingresos3%
US$ 3.5 B
Margen operativo12%
11.5%
Flujo de caja libre25%
US$ 0.1 B
Deuda neta
US$ 1.9 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 3.1B
P/E20.5x
EV/EBITDA8.7x
FCF yield3.9%
ROIC7.1%
Margen operativo11.5%
Crecim. ingresos-2.7%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 30 jun
H.B. Fuller Q2 Earnings Call Flags Pricing, AMS Ambitions
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
seekingalpha.com · 26 jun
H.B. Fuller: Overreaction, Or Proof Of Slowdown
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
seekingalpha.com · 25 jun
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
businesswire.com · 25 jun
Ancora Condemns H.B. Fuller's Decision to Ignore Shareholder Opposition and Proceed with the Reckless Acquisition of Advanced Medical Solutions
CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) today released the below statement regarding H.B. Fuller Company (NYSE: FUL) (“H.B. Fuller” or the “Company”) and Advanced Medical Solutions Group plc (“AMS”). Previously, Ancora issued a letter to H.B. Fuller's Board of Directors (the “Board”) regarding its contemplated acquisition of AMS. Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President.
benzinga.com · 25 jun
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday.
proactiveinvestors.co.uk · 25 jun
Advanced Medical Solutions shares jump 16% on £659 million takeover by US adhesives group H.B. Fuller
Shares in Advanced Medical Solutions Group (AIM:AMS) rose 16% to 278.14p after the company agreed to a recommended cash takeover by H.B. Fuller, the US adhesives group, valuing it at about £659 million.
reuters.com · 25 jun
H.B. Fuller to buy UK's Advanced Medical Solutions for $942 million
U.S.-based adhesives maker H.B. Fuller will buy Advanced Medical Solutions Group in a cash ​deal that values the British medical supplier at about £715 ‌million ($942.1 million) including debt, the companies said on Thursday.
businesswire.com · 25 jun
H.B. Fuller Announces Offer to Acquire Advanced Medical Solutions
ST. PAUL, Minn.--(BUSINESS WIRE)--H.B. Fuller Company (“H.B. Fuller” or “the Company”) (NYSE: FUL), the world's largest pureplay adhesives company, today announced it has made a recommended cash offer to acquire Advanced Medical Solutions Group plc (“AMS”) (LSE:AMS). “This transaction is a rare opportunity to advance the evolution of our portfolio.” said Celeste Mastin, President and CEO of H.B. Fuller. “We have long been clear that medical is a core strategic growth market for H.B. Fuller give.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.